Response to Secukinumab Shows Variations Across Psoriatic Arthritis Clusters
Researchers compared the effect of secukinumab on the quality of life of patients with very early and established psoriatic arthritis.
Researchers compared the effect of secukinumab on the quality of life of patients with very early and established psoriatic arthritis.
Researchers determined the effect of disease-modifying antirheumatic drug therapy on patients with early rheumatoid arthritis with cardiovascular disease.
Researchers compared the hospitalization outcomes of patients with ischemic stroke with and without a secondary diagnosis of systemic sclerosis.
Researchers assessed the interchangeability of 2 measures of minimal disease activity in psoriatic arthritis.
Researchers determined the real-world incidence of acute gout prophylaxis (AGP) while prescribing a xanthine oxidase inhibitor, and described the characteristics of AGP prescribing in reducing gout flares.
Researchers investigated the incidence rates of interstitial lung disease in patients with rheumatoid arthritis receiving tofacitinib and identified potential risk factors.
Researchers evaluated the role of anti-CD74 antibodies in the diagnosis of axial spondyloarthritis and their association with disease duration and activity.
Researchers identified secular trends associated with systemic sclerosis mortality over 48 years.
Researchers assessed whether febuxostat increased the risk of developing cardiovascular events, death from cardiac-cause, and all-cause mortalities.
Researchers evaluated drug retention and predictors for drug retention among patients with psoriatic arthritis receiving first-line conventional synthetic DMARD monotherapy.